Neurosense TherapeuticsNRSN
13F holders, Q2 2025 (June 30)17holders +6
8new positions
3sold out
1famous investor
$1.89avg. 13F price*
At the end of Q2 2025, 17 institutions reported holding Neurosense Therapeutics Ltd. (NRSN) in their 13F filings, up 6 from Q1 2025. 8 opened new positions and 3 sold out. The largest holders were Citadel Advisors ($282K), Morgan Stanley ($151K) and Yorkville Advisors Global, LP ($113K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Neurosense Therapeutics Ltd.
- CUSIP
- M74240108
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 8 | $529K |
| Exits | 3 | $55K |
All 13F filers, Q1 2025 → Q2 2025: 317,107 shares bought and 61,955 shares sold, net +255,152 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 17 holders
| Citadel Advisors | 0.00% | New | 149,243 | $282K |
| Morgan Stanley | 0.00% | Add +58.2% | 79,900 | $151K |
| Yorkville Advisors Global, LP | 0.03% | — | 60,000 | $113K |
| Squarepoint Ops LLC | 0.00% | New | 49,925 | $94K |
| Meitav Investment House Ltd. | 0.00% | No change | 40,000 | $76K |
| Jane Street Group, LLC | 0.00% | New | 28,689 | $54K |
| HRT Financial LP | 0.00% | New | 21,694 | $41K |
| Commonwealth Equity Services, LLC | 0.00% | Add +22.2% | 21,080 | $40K |
| Geode Capital Management, LLC | 0.00% | No change | 15,870 | $30K |
| Marshall Wace, LLP | 0.00% | New | 11,828 | $22K |
| Jones Financial Companies LLLP | 0.00% | New | 10,919 | $21K |
| BNP Paribas Financial Markets | 0.00% | New | 6,800 | $13K |
| Hurley Capital, LLC | 0.01% | Reduce -25.0% | 6,530 | $12K |
| SBI Securities Co., Ltd. | 0.00% | Add +2445.7% | 4,455 | $8K |
| UBS Group AG | 0.00% | Reduce -29.2% | 1,611 | $3K |
| Cwm, LLC | 0.00% | No change | 1,000 | $2K |
| Total Investment Management Inc. | 0.00% | New | 500 | $945 |
"% of holder's portfolio" is NRSN's weight in each manager's 13F, not the share of Neurosense Therapeutics Ltd. the manager owns.